Study M582
Study name | Zhao J 2019 |
Title | A comprehensive metabolomics investigation of hippocampus, serum, and feces affected by chronic fluoxetine treatment using the chronic unpredictable mild stress mouse model of depression |
Overall design | In this study, a metabolomic investigation of depression and chronic fluoxetine treatment was conducted using a chronic unpredictable mild stress (CUMS) model with C57BL/6N mice. C57BL/6N mice were divided into the following 4 groups (n = 7 in each group): (1) control group, (2) control + fluoxetine group (control plus fluoxetine treatment at the dose of 20 mg/kg), (3) CUMS group (stressor plus vehicle treatment), and (4) CUMS + fluoxetine group (stressor plus fluoxetine treatment at the dose of 20 mg/kg). The CUMS stress procedure lasted for 5 weeks, and drugs were administered via intragastric once per day during the last 4 weeks of the model building period. Hippocampus, serum, and feces samples collected from four groups were subjected to metabolomic profiling based on ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry. |
Study Type | Type1; Type2; Type3; |
Data available | Unavailable |
Organism | Mouse; C57BL/6N mouse; |
Categories of depression | Animal model; Chronic mild stress model; Chronic mild stress model; Healthy individuals; Healthy individuals; Healthy individuals; |
Criteria for depression | Forced swimming test, tail suspension test |
Sample size | 28 |
Tissue | Central; Brain; Hippocampus; Peripheral; Blood; Serum; Peripheral; Faece; Faece; |
Platform | MS-based; LC-MS: Acquity UPLC system (Waters Co., Milford, MA, USA) with Waters Acquity Xevo G2 Q-TOF tandem mass spectrometer (Waters Corp., Manchester, UK); |
PMID | |
DOI | |
Citation | Zhao J, Jung YH, Jin Y, et al. A comprehensive metabolomics investigation of hippocampus, serum, and feces affected by chronic fluoxetine treatment using the chronic unpredictable mild stress mouse model of depression. Sci Rep. 2019;9(1):7566. |
Metabolite | Oleic acid; L-Tryptophan; Arachidonic acid; Tyramine; Cholic acid; Chenodeoxycholic acid; LysoPC(16:0); Indoxyl sulfate; Leucine or Isoleucine; Docosahexaenoic acid; Inosine; LysoPC(18:0); 5-Thymidylic acid; Inosinic acid; LysoPC(18:1); LysoPC(18:2); LysoPC(15:0/0:0); Oleamide; Glutathione; LysoPC(16:1/0:0); Palmitic amide; Deoxycholic acid; LysoPC(20:4); Alpha-Linolenic acid; LysoPE(0:0/20:1); 3-O-Sulfogalactosylceramide (d18:1/24:1); LysoPE(0:0/16:0); LysoPC(20:3); 3-Oxo-4,6-choladienoic acid; Hydrocinnamic acid; PC(o-22:1/20:4); LysoPE(0:0/18:2); LysoPE(0:0/20:2); Oxooctadecanoic acid; MG(0:0/18:2/0:0); N-Formyl-L-glutamic acid; LysoPE(18:1/0:0); MG(18:0/0:0/0:0); Beta-Citryl-L-glutamic acid; Ceanothenic acid; N-Decanoylglycine; Trans-Hexa-dec-2-enoic acid; 6-Hydroxyoctadecanoic acid; (9S,10S)-10-hydroxy-9-(phosphonooxy)octadecanoate; Cervonoyl ethanolamide; PE(20:3/P-18:1); PC(18:0/22:1); LysoPE(0:0/22:4); LysoPI(16:0/0:0); |
